Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer.

摘要: ZD1839 is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in treatment of non-small cell lung cancer (NSCLC). We now present a case diffuse alveolar damage (DAD) that developed 67-year-old man treated with ZD1839. On day 8 administration, patient complained dyspnea new-ground glass opacity was apparent on chest X-ray computed tomography scan. Despite high-dose steroid therapy, died 13 days after first administration Postmortem analysis tissue revealed pattern DAD. No evidence infection or other specific etiologies apparent. This reported respiratory failure NSCLC. Physicians should therefore be aware potential pulmonary toxicity